BioCryst takes on Takeda, CSL with FDA approval for Orladeyo, the first pill to prevent HAE attacks

BioCryst takes on Takeda, CSL with FDA approval for Orladeyo, the first pill to prevent HAE attacks

Submitted by admin on December 5, 2020 - 11:26pm
Source: 
Fierce Pharma
News Tags: 
Biocryst
Orladeyo
HAE
FDA
Takeda
CSL Behring
Headline: 
BioCryst takes on Takeda, CSL with FDA approval for Orladeyo, the first pill to prevent HAE attacks
snippet: 

Ready to take on established competition from Takeda and CSL Behring, BioCryst Pharmaceuticals has scored FDA approval for Orladeyo, the first oral option to prevent hereditary angioedema (HAE) attacks in patients 12 and older.

Do Not Allow Advertisers to Use My Personal information